GNI Group Ltd. | Income Statement

Fiscal year is January-December. All values JPY Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
184
475
1,017
1,307
2,648
5,019
Cost of Goods Sold (COGS) incl. D&A
175
161
241
190
495
848
Gross Income
9
314
776
1,117
2,153
4,171
SG&A Expense
794
856
1,429
1,393
2,009
3,529
EBIT
785
-
653
276
145
641
Unusual Expense
4
147
-
-
14
-
Non Operating Income/Expense
12
116
2
109
51
260
Interest Expense
9
11
23
20
34
39
Pretax Income
786
286
670
386
137
365
Income Tax
46
-
1
80
109
173
Equity in Affiliates
-
-
-
-
-
-
Consolidated Net Income
832
286
669
466
28
192
Net Income
731
317
623
513
175
200
Net Income After Extraordinaries
731
317
623
513
175
200
Net Income Available to Common
731
317
623
513
175
200
EPS (Basic)
71.60
28.20
54.90
45.10
14.00
14.82
Basic Shares Outstanding
10
11
11
11
13
14
EPS (Diluted)
71.55
27.50
53.62
44.43
13.97
14.82
Diluted Shares Outstanding
10
12
12
12
13
14
EBITDA
749
509
592
210
234
795
Non-Operating Interest Income
1
5
28
19
24
22
Minority Interest Expense
101
31
45
47
203
392
Equity in Affiliates (Pretax)
-
-
20
-
34
-

About GNI Group

View Profile
Address
Nihonbashi Honcho YS Bldg., 3/F
Tokyo Tokyo 103
Japan
Employees -
Website http://www.gnipharma.com
Updated 07/08/2019
GNI Group Ltd. engages in the development, research, manufacture, and sales of pharmaceutical drugs and traditional Chinese medicines. It operates through Japan and China segments. The Japan segment deals with licensing, preclinical studies, clinical trials, and sales.